Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.03
-0.37 (-6.85%)
At close: Jun 27, 2025, 4:00 PM
5.07
+0.04 (0.76%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Recursion Pharmaceuticals stock ranges from a low of $5.00 to a high of $10. The average analyst price target of $7.00 forecasts a 39.17% increase in the stock price over the next year.
Price Target: $7.00 (+39.17%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $5 | Hold | Maintains | $8 → $5 | -0.60% | Jun 16, 2025 |
| Needham | Needham | Strong Buy Maintains $11 → $8 | Strong Buy | Maintains | $11 → $8 | +59.05% | May 6, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $10 → $8 | Hold | Maintains | $10 → $8 | +59.05% | Apr 10, 2025 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +118.69% | Apr 8, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +19.28% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
72.67M
from 58.84M
Increased by 23.51%
Revenue Next Year
111.82M
from 72.67M
Increased by 53.87%
EPS This Year
-1.49
from -1.69
EPS Next Year
-1.20
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 121.3M | 231.5M | 357.0M |
| Avg | 72.7M | 111.8M | 297.2M |
| Low | 44.0M | 54.6M | 237.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 106.1% | 218.6% | 219.3% |
| Avg | 23.5% | 53.9% | 165.8% |
| Low | -25.3% | -24.9% | 112.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.29 | -0.89 | -0.49 |
| Avg | -1.49 | -1.20 | -0.78 |
| Low | -1.60 | -1.43 | -1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.